Skip to main content

Table 1 Pregabalin and duloxetine drug-drug interactions

From: A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine

Severity Brief description of potential harm due to DDI Interacting drug
Pregabalin   
Major Reduced pregabalin effectiveness naproxen, ketorolac
Duloxetine
Contraindicated CNS toxicity or serotonin syndrome isocarboxazid, linezolid, procarbazine, rasagiline, selegiline, tranylcypromine
  Increased serum concentrations of interacting drug and risk of cardiac arrhythmia thioridazine
  Increased risk of extrapyramidal reactions or neuroleptic malignant syndrome metoclopramide
  Increased risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions methylene blue
Major Increased interacting drug plasma level and Increased risk of QT prolongation clozapine
  Increased risk of bleeding antiplatelet agents, escitalopram
  Increased risk of serotonin syndrome almotriptan, citalopram, cyclobenzaprine, desvenlafaxine, dextromethorphan, eletriptan, fluoxetine, fluvoxamine, frovatriptan, hydroxytryptophan, lithium, lorcaserin, methadone, milnacipran, naratriptan, paroxetine, rizatriptan, sertraline, sumatriptan, tapentadol, tramadol, trazodone, tryptophan, venlafaxine, zolmitriptan
  Increased risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions vilazodone
  Increased serum concentrations of interacting drugs and an Increased risk of cardiotoxicity class 1C antiarrhythmic agents
Moderate decreased plasma concentrations of the active metabolites of interacting drug tamoxifen
  Increased duloxetine serum concentrations and risk of adverse effects ciprofloxacin, clobazam, enoxacin, mirabegron, quinidine
  Increased exposere to interacting drug and potential toxicity phenothiazines, tamsulosin, tricyclic antidepressants
  Increased risk of bleeding acenocoumarol, dabigatran, dalteparin, danaparoid, desirudin, enoxaparin, fondaparinux, nonsteroidal anti-inflammatory agents, phenindione, phenprocoumon, tinzaparin, warfarin
  1. Source: Micromedex 2.0 (Truven Health Analytics Inc., Greenwood Village, CO), accessed May 31, 2013. Drugs with primary use in the hospital setting (e.g., lepirudin) were excluded.